Evidence map›Paper›PMID 37014551›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2023

Small extracellular vesicles promote invadopodia activity in glioblastoma cells in a therapy-dependent manner.

Clarissa A Whitehead, Haoyun Fang, Huaqi Su, Andrew P Morokoff, Andrew H Kaye, Eric Hanssen, Cameron J Nowell, Katharine J Drummond, David W Greening, Laura J Vella and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Clarissa A WhiteheadDepartment of Surgery, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0003-1584-8138
Haoyun FangMolecular Proteomics, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-6582-1975
Huaqi SuCentre for Stem Cell Systems, The University of Melbourne, Parkville, VIC, Australia.
Andrew P MorokoffDepartment of Surgery, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-5159-3438
Andrew H KayeDepartment of Surgery, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0001-5049-8861
Eric HanssenDepartment of Biochemistry and Pharmacology, The University of Melbourne, Parkville, VIC, 3010, Australia.ORCID http://orcid.org/0000-0002-4064-1844
Cameron J NowellDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, 3052, Australia.ORCID http://orcid.org/0000-0002-8662-9840
Katharine J DrummondDepartment of Surgery, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-8152-2120
David W GreeningMolecular Proteomics, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-7516-485X
Laura J VellaDepartment of Surgery, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-1869-6291
Theo MantamadiotisDepartment of Surgery, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0003-3971-5380
Stanley S StylliDepartment of Surgery, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia. sstylli@unimelb.edu.au.ORCID http://orcid.org/0000-0002-3505-7387
The Royal Melbourne Hospital · AUBaker Heart and Diabetes Institute · AUThe University of Melbourne · AUMonash University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe therapeutic efficacy of radiotherapy/temozolomide treatment for glioblastoma (GBM) is limited by the augmented invasiveness mediated by invadopodia activity of surviving GBM cells. As yet, however the underlying mechanisms remain poorly understood. Due to their ability to transport oncogenic material between cells, small extracellular vesicles (sEVs) have emerged as key mediators of tumour progression. We hypothesize that the sustained growth and invasion of cancer cells depends on bidirectional sEV-mediated cell-cell communication.

methodsInvadopodia assays and zymography gels were used to examine the invadopodia activity capacity of GBM cells. Differential ultracentrifugation was utilized to isolate sEVs from conditioned medium and proteomic analyses were conducted on both GBM cell lines and their sEVs to determine the cargo present within the sEVs. In addition, the impact of radiotherapy and temozolomide treatment of GBM cells was studied.

resultsWe found that GBM cells form active invadopodia and secrete sEVs containing the matrix metalloproteinase MMP-2. Subsequent proteomic studies revealed the presence of an invadopodia-related protein sEV cargo and that sEVs from highly invadopodia active GBM cells (LN229) increase invadopodia activity in sEV recipient GBM cells. We also found that GBM cells displayed increases in invadopodia activity and sEV secretion post radiation/temozolomide treatment. Together, these data reveal a relationship between invadopodia and sEV composition/secretion/uptake in promoting the invasiveness of GBM cells.

conclusionsOur data indicate that sEVs secreted by GBM cells can facilitate tumour invasion by promoting invadopodia activity in recipient cells, which may be enhanced by treatment with radio-chemotherapy. The transfer of pro-invasive cargos may yield important insights into the functional capacity of sEVs in invadopodia.

Indexed as

Extracellular VesiclesGlioblastomaPodosomesHumansProteomicsTemozolomideTemozolomideExtracellular vesiclesGlioblastomaInvadopodiaRadiotherapyTemozolomide

Identifiers

PMID37014551
PMCPMC10356899
OpenAlexW4362523444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.